Lexicon Pharmaceuticals
LXRX
127 hedge funds and large institutions have $471M invested in Lexicon Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 49 increasing their positions, 20 reducing their positions, and 17 closing their positions.
576% more call options, than puts
Call options by funds: $4.21M | Put options by funds: $622K
145% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 20
53% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 17
13% more capital invested
Capital invested by funds: $418M → $471M (+$53.3M)
7% more ownership
Funds ownership: 70.17% → 77.17% (+7%)
7% more funds holding
Funds holding: 119 → 127 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$103M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$44.5M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
+$14.9M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.34M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$4.05M |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$3.37M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$766K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$704K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$697K |
LXRX Hedge Fund Activity: Q2 2024 in Review
127 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q2 2024, worth a combined $471M — up 13% from $418M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new LXRX positions and 17 closed out — a net gain of 9 holders — while 49 added to existing stakes and 20 trimmed.
The largest buyer was Artal Group, adding an estimated $103M. The largest seller was BVF Inc, exiting entirely with an estimated $4.05M sold.
- 127 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q2 2024, up from 119 in Q1 2024.
- Funds reported $471M of Lexicon Pharmaceuticals stock for Q2 2024, up 13% quarter-over-quarter.
- 26 funds opened new Lexicon Pharmaceuticals positions in Q2 2024 and 17 closed out, a net change of +9 holders.
- The largest Lexicon Pharmaceuticals buyer in Q2 2024 was Artal Group, an estimated $103M added.
- The largest Lexicon Pharmaceuticals seller in Q2 2024 was BVF Inc, an estimated $4.05M sold.
Based on aggregated 13F filings for Q2 2024.